Scary Diet Supplement

Whoa partner–be careful on those dietary supplements. This one is lethal.
You might stay away from Oxy ELITE Pro, promoted as a weight loss, muscle gain supplement.
Yeeeow. Sorry that I frustrated people with this link. Forgot it is a password site.
Here is the intro to the article that appeared at Morbidity and Mortality Weekly.
Morbidity & Mortality Weekly Report
Notes From the Field
Acute Hepatitis and Liver Failure Following the Use of a Dietary Supplement Intended for Weight Loss or Muscle Building
May-October 2013
Sarah Y. Park, MD, Melissa Viray, MD, David Johnston, MPH, Ethel Taylor, DVM, Arthur Chang, MD, Colleen Martin, MSPH, Joshua G. Schier, MD, Lauren S. Lewis, MD, Kara M Levri, MD, Kevin Chatham-Stephens, MD
Disclosures
Morbidity and Mortality Weekly Report. 2013;62(40):817-819.
Print
Email
Topic Alert
Receive an email from Medscape whenever new articles on this topic are available.
Personal Alert Add Sports Medicine to My Topic Alert
Drug & Reference Information
Disseminated Intravascular Coagulation
Pediatric Fulminant Hepatic Failure
Follow-up of the NICU Patient
On September 9, 2013, the Hawaii Department of Health (HDOH) was notified of seven patients with severe acute hepatitis and fulminant liver failure of unknown etiology. Patients were previously healthy and sought medical care during May-September 2013. Clinicians reported that the seven patients had all used OxyELITE Pro, a dietary supplement marketed for weight loss and muscle gain, before illness onset.
The HDOH, with the CDC and the Food and Drug Administration (FDA), initiated a public health investigation including patient interviews, medical chart reviews, and collection of supplement samples for analysis. Subsequently, a case was defined as acute hepatitis of unknown etiology occurring on or after April 1, 2013 in a person who had consumed a weight loss or muscle-building dietary supplement within the previous 60 days and had a serum alanine aminotransferase level greater than or equal to four times the upper limit of normal (>160 IU/L) and a total bilirubin level greater than or equal to two times the upper limit of normal (>2.5 mg/dL) and a negative evaluation for infections including viral hepatitis. Excluded were other etiologies such as pre-existing autoimmune hepatitis, chronic alcohol use, and chronic liver diseases such as primary biliary cirrhosis, primary sclerosing cholangitis, Wilson’s disease, and hemochromatosis.
Clinicians reported 45 possible cases to the Hawaii DOH in response to a public health alert. Of those, 29 have been identified as cases. The patients have a median age of 33 years (range: 16–66); 14 (48%) were male. The date of first reported laboratory test was used as a proxy for illness onset and ranged from May 10 through October 3, 2013 (Figure). The most commonly reported symptoms included loss of appetite, light-colored stools, dark urine, and jaundice. Median laboratory values reported at the peak of illness were: aspartate aminotransferase 1,128 IU/L (range: 104–2,184, upper limit of normal ~40); alanine transaminase 1,793 IU/L (range: 347–3,091, upper limit of normal ~40); alkaline phosphatase 150 IU/L (range: 68–251, upper limit of normal ~120); and total bilirubin 12.6 mg/dL (range: 2.8–39.6, upper limit of normal ~1.2). Ten patients had liver biopsy data available at the time of this report; seven had histology consistent with hepatitis from drug/toxic injury, with findings including hepatocellular necrosis and cholestasis. Eleven (38%) patients were hospitalized, with a median duration of 7 days (range: 1–45). One patient died, two patients received liver transplants, and two remain hospitalized; all other hospitalized patients have been discharged.
Click to zoom
(Enlarge Image)
Figure.
Number of cases by date of first reported laboratory result*
* Three cases with a first reported laboratory result in October are not shown.